IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Diagnosis and Risk Stratification of Plasma Cell Disorders: To Treat or Not to Treat December 7, 2019 ASH Upfront Therapy for the ASCT-Eligible Patient: Advances in Induction, ASCT, Consolidation, and Maintenance Therapy December 7, 2019 ASH Evaluation of Upfront Therapy for the ASCT-Ineligible Patient December 7, 2019 ASH The Current Therapeutic Landscape for Relapsed or Refractory Multiple Myeloma December 7, 2019 ASH 2020 Treatment Algorithm for Multiple Myeloma December 7, 2019 ASH Approaches To Achieve the Best Possible Outcomes in Myeloma December 6, 2019 ASH Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta Exposed and Triple Class-Refractory MM December 5, 2018 ASH Maintenance Therapy with Ixazomib Significantly Prolongs Progression-Free Survival Following ASCT in Patients with NDMM: Phase 3 Tourmaline-MM3 Trial December 4, 2018 ASH Phase 2 Randomized Study of Daratumumab, Bortezomib, Lenalidomide, and Dex Vs. Vrd in Patients with Newly Diagnosed Multiple Myeloma December 4, 2018 ASH Tandem Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific CAR T-Cells for High Risk MM December 4, 2018 ASH Preliminary Results from a Phase I Study of Isatuximab in Combination with Bortezomib, Lenalidomide, Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplant December 4, 2018 ASH Carfilzomib-Lenalidomide-Dexamethasone Induction-Autologous Transplant-KRd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction-ASCT-KCd Consolidation December 4, 2018 ASH Load More
